Objective-Elevated lipoprotein(a) [Lp(a)] is a causal, independent risk factor for cardiovascular disease and aortic stenosis.
E levated lipoprotein(a) [Lp(a)] is a genetic, causal, independent risk factor for the development of cardiovascular disease (CVD) and calcific aortic valve stenosis. [1] [2] [3] [4] [5] [6] [7] The European Atherosclerosis Society Consensus Panel (EAS) recommended that Lp(a) levels should be measured in patients with intermediate or high CVD risk and that desirable Lp(a) levels should be below the 80th percentile of the population distribution, which roughly corresponds to <50 mg/dL (≈<125 nmol/L). 8 This threshold was based on prevalence of Lp(a) values in 6000 initially healthy subjects in a Danish Caucasian population from the Copenhagen General Population Study. However, in epidemiological and Mendelian randomization studies performed in primary care populations with no prior CVD, including from Copenhagen, increased CVD risk actually starts as low as 25 to 30 mg/dL. [1] [2] [3] 9 In secondary prevention populations consisting of patients with prior CVD that are optimally treated with statins and antiplatelet agents, recurrent events seem to begin at values >50 mg/dL. [10] [11] [12] Lp(a) is composed of apolipoprotein(a) [apo(a)] covalently bound to apolipoprotein B (apoB)-100 of a low-density lipoprotein (LDL)-like particle. It is atherogenic because of the LDL moiety and also from additional proinflammatory and prothrombotic mechanisms from the apo(a) moiety. Oxidized phospholipids are present in both the lipid phase of Lp(a) and covalently bound to apo(a) at KIV 10 to KV junction, with an intact lysine-binding pocket in KIV 10 being integral in mediating binding oxidized phospholipids. 13 The oxidized phospholipid content of Lp(a), as measured by the oxidized phospholipids-apoB assay, is a major determinant of risk for CVD and calcific aortic value stenosis. 6, [14] [15] [16] [17] [18] In view of these differences in CVD risk among general populations and specifically in patients, it is important to validate Lp(a) thresholds more broadly using data from other counties and as importantly to do it in actual patients in addition to general population thresholds. Our goal was to assess the frequency distribution of Lp(a) mass levels and determine percentile thresholds in a US patient population derived from a referral laboratory and a tertiary referral center. tiles, LDL-C linearly increased from 99.1 to 108.6 mg/dL. In contrast, removing the Lp(a) cholesterol component of Lp(a) showed that the corrected LDL-C was actually decreasing from 98.1 to 78.5 mg/dL with increasing Lp(a) mass. Total cholesterol, high-density lipoprotein cholesterol, apoAI, and non-high-density lipoprotein cholesterol were all increasing with increasing Lp(a), but triglycerides decreased across quintiles. hsCRP was also increasing linearly with Lp(a) quintiles or Lp(a) cutoffs of >30 and >50 mg/dL (Tables 1 and 2) .
Frequency Distribution of Lp(a), LDL-C, and ApoB
As expected, Lp(a) mass levels were skewed rightward (tail is longer; Figure 1A ). In contrast, both LDL-C and apoB were distributed in a normal fashion ( Figure 1B and 1C, respectively).The frequency distribution was further analyzed by sex in 265 601 females ( Figure 1D ) and 255 542 males ( Figure  1G ). Lp(a) mass was skewed rightward, but both LDL-C and apoB were distributed in a normal fashion in females ( Figure  1E and 1F) and males ( Figure 1H and 1I).
Association Between Lp(a) Mass Quartiles of LDL-C, hsCRP, Fasting Glucose, Insulin, and Hemoglobin A1c
Very weak but statistically significant Spearman correlations were noted between Lp(a) and lipid, lipoprotein, and hsCRP variables ( Table 3) . Lp(a) levels were further analyzed by quartiles of LDL-C in the entire group and by fasting glucose, insulin, and hemoglobin A1c in a subset of 54 665 patients with concomitant Lp(a) mass data (Table 4 ). In each quartile of LDL-C, the Lp(a) levels were higher, from 29.3 in lowest to 38.3 in the highest quartile. Interestingly, similar data were noted in quartiles of hemoglobin A1c, with Lp(a) ranging from 27.8 to 35.2 mg/dL from the lowest to the highest quartile. No relationship was noted with fasting glucose. Although the data were significant for insulin levels, the quartiles were not associated in a linear fashion.
Tertiary Care Center Data
At the tertiary referral center, a total of 915 patients had an Lp(a) measurement from January 1, 2012, to December 31, 2015. A total of 1686 Lp(a) assays were performed during this time (417/y); thus, 45.7% of assays were a repeat measure.
The mean±SD Lp(a) levels were 40±49 mg/dL, and median (interquartile range) levels were 19 (6-62) mg/dL, with a range of <2 to 331 mg/dL. Lp(a) levels >30 and >50 mg/dL were present in 39.5% and 29.2% of subjects, respectively ( Figure 2 ). Lp(a) percentile levels at 75%, 80%, 90%, 95%, and 99% were reflected as Lp(a) >62.0, >72.0, >106.4, >147.6, and 212.4 mg/dL, respectively.
Discussion
This study represents the largest data set of Lp(a) mass levels in patients. In the referral laboratory population of outpatients, 35.0% had Lp(a) levels >30 mg/dL, which is the usual upper limit of normal Lp(a) in most US clinical laboratories, and 24.0% of patients had Lp(a) >50 mg/dL, the threshold suggested by the EAS Consensus document. 8 In the tertiary care medical center data set, remarkably, 39.5% and 29.2% had Lp(a) levels >30 and >50 mg/dL, respectively.
The observations in the referral laboratory that 24.0% of patients had Lp(a) levels >50 mg/dL, despite being in patients rather than free-living community individuals, are higher to the ≈20% of individuals with Lp(a) >50 mg/dL derived from nonfasting fresh serum samples from 3000 men and 3000 women from the Copenhagen General Population Study collected from 2003 to 2004. 8 In a subsequent study in 8720 Danish participants from the Copenhagen City Heart Study, using an in-house assay, 20% of individuals had Lp(a) >47 mg/dL. 2 In a larger study of 34 829 individuals from the Copenhagen General Population Study and the Copenhagen City Heart Study combined, 20% of individuals had Lp(a) at what appeared to be slightly below 50 mg/dL using the Denka Seiken assay. The relative concordance of values from Copenhagen and the current study reflecting a US population, using the same Denka Seiken assay, suggest that the percentile values are comparable and reliable as appropriate patient and population thresholds. Additionally, examination of the frequency distribution of the current study with the Copenhagen data 8 suggests a similar right skewness of the data, with most patients having low values and a long tail of increasingly elevated values.
Although Lp(a) <50 mg/dL has been suggested by the EAS as a desirable level, 8 this value is based on population thresholds and not on evidence-based data of where CVD risk of Lp(a) begins. 9 In fact, in the several Copenhagen studies published to date in general populations, from which the EAS recommendations were actually derived, the data most strongly support a risk starting at >≈20 mg/dL or the 67th percentile. 2, 19, 20 Consistent with these data, in the Emerging Risk Factor Collaboration, Lp(a) levels displayed a curvilinear relationship, with the curve rising very slowly until ≈24 mg/dL, then rising almost linearly with increasing levels. 1 Similarly, in the PROCARDIS study (Precocious Coronary Artery Disease), levels of Lp(a) at which risk accumulated started ≈25 mg/dL and rose linearly with both Lp(a) levels and the number of LPA variant alleles that are known to be associated with increasing Lp(a) levels. 3 In the JUPITER trial (Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin) of high-risk primary prevention, in rosuvastatin-treated patients, the risk of Lp(a) persisted at >50 nmol/L, which is ≈20 mg/dL. 11 Finally, in a nested case-control study from EPIC-Norfolk, using a unique methodology of 2 different assays in the same population, the 80% thresholds were at 36 and 24 mg/dL for the Randox and an in-house research Lp(a) ELISA developed at University of California San Diego (UCSD; 21 this is not the assay the UCSD Medical Center uses), respectively, a level at which the highest risk of coronary artery disease was also noted. 9 This suggests that the >30 mg/dL cutoff used in most laboratories is a more accurate reflector of risk in primary prevention populations, a number that was first suggested over 35 years ago. 22 Regarding appropriate units, some European laboratories report data as mg/L, so that this lower level cutoff would be >300 mg/L. In addition, some laboratories report Lp(a) levels as nmol/L, which can be roughly approximated to Lp(a) mass by multiplying by 2.5×, but this may actually range from ≈1.7 to 3.3. It is to be emphasized that a conversion factor of changing nmol/L to mg/dL is not entirely appropriate for Lp(a). Unlike cholesterol and triglycerides that have a fixed chemical mass and molecular weight, Lp(a) consists of not only the mass of apoB and apo(a) but also the mass of carbohydrates on apo(a), as well as cholesterol, cholesteryl esters, and phospholipids. Because these values may be different among Lp(a) particles of different patients, a single conversion factor from mass of the entire Lp(a) particle to nmol/L of apo(a) is not appropriate. This speaks to the need to standardize and report all commercially available assays to a common standard in the future.
Additional insights from this large data set included that even though LDL-C and Lp(a) were not correlated strongly, when analyzed by quartiles of each, both LDL-C and Lp(a) tended to be higher in each respective quartile. However, if LDL-C was corrected for the Lp(a) cholesterol content, using a mathematical equation as LDL-C corr = LDL-C−(Lp(a)×0.3), 23 the true LDL-C tended to decrease with increasing Lp(a). The apoB data strongly reflected the LDL-C data. Although this equation is not fully validated and may not perfectly reflect the true LDL-C, it nonetheless points to the fact that as the liver makes more apo(a) to generate Lp(a), less apoB ultimately becomes LDL-C. This has implications for proper identification of LDL-C and Lp(a)-mediated risk when simply measuring LDL-C, which is actually a misnomer, and, in fact, is a combination of LDL-C and Lp(a) cholesterol, as recently discussed. 23 Additionally, it was shown that hsCRP levels were higher as Lp(a) increased. Although this seems intuitive because of the fact that both reflect inflammatory pathways, 24 prior data from the general community in the Copenhagen studies did not show such an association. The differences between the studies may be because of the fact that the current study includes all patients, whereas in the Copenhagen studies, the subjects were individuals from the general community. The studies are also temporally not congruent because the current study represents a more recent analysis, whereas some of the Copenhagen data are over 20 years old, and it is well known that populations and risk factors have changed, particularly in regards to increasing obesity, which may increase hsCRP globally. The current population also had a high body mass index consistent with higher hsCRP levels. An inverse association was also noted with Lp(a) and triglycerides, which has been noted previously. 25 Finally, although the prevalence of diabetes mellitus was not known in this study, there was a clear linear trend of increasing hemoglobin A1c with Lp(a), but no clear association with fasting glucose or insulin. These data tend to go against the several studies showing a higher rate of incident diabetes mellitus with very low Lp(a) (1-4 mg/dL), but the data likely reflect the reality of the complexities of studying patients who are potentially on treatment versus the community cohorts.
In the UCSD database that encompasses a range of patients with high-risk primary prevention, CVD, and aortic stenosis, the 80th percentile cutoffs were higher than both the referral laboratory and Copenhagen databases. These percentages clearly represent referral patterns to a tertiary care center, as well as derivation of patients from high-risk populations, such as patients from the Lp(a) and lipid clinics and cardiology practices and cardiac catheterization laboratories that treat patients with advanced CVD and acute cardiovascular events. This also suggests that a higher proportion of such sicker patients with elevated Lp(a) accumulate in higher risk settings.
Interestingly, in secondary prevention settings where patients are generally on maximal secondary prevention measures, such as in the AIM-HIGH 12 (Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglyceride and Impact on Global Health Outcomes) and LIPID 10 trials (Long-Term Intervention with Pravastatin in Ischaemic Disease), the risk of recurrent CVD events was present in the fourth quartiles, which represented Lp(a) >125 nmol/L (or >≈50 mg/dL) and >73.7 mg/dL, respectively. Therefore, setting thresholds and levels at which one might assign risk has to take into account the prevalence of the extent of CVD and that thresholds may need to be different for the general community versus actual patients. 9 Another layer of complexity in establishing Lp(a) cutoffs that has not been fully understood is that significant racial and ethnic differences exist in Lp(a) levels, with the highest levels generally in descending order being present in Blacks, Asian Indians, Caucasians, Hispanics, and East Asians. [26] [27] [28] It was previously thought that Blacks do not have the same risk of CAD and stroke from Lp(a) unless they carried small isoforms, but a recent large study from the ARIC study (Atherosclerosis Risk in Communities) 29 with 20-year follow-up suggests similar risk between Whites and Blacks. Interestingly, Blacks have 2-to 4-fold higher Lp(a) levels than Whites within the same isoform size classes, as well as a Gaussian apo(a) isoform distribution as opposed to Whites and Hispanic who have a skewed distribution. 26 In addition, Blacks generally lack the 2 most common isoforms present in Europeans, rs10455872 and rs3798220, but more frequently carry rs9457951, which is associated with high Lp(a) levels, but this only explains a small percentage of plasma Lp(a) levels. 30 Finally, recent data from MESA (Multi-Ethnic Study of Atherosclerosis) suggest that 30 mg/dL cutoff for Lp(a) is appropriate for Black patients but not appropriate for White and Hispanic individuals in whom >50 mg/dL cutoff should be considered. 28 However, this observation needs to be replicated because of its small number of events and wide confidence intervals. It is apparent that race-specific cutoffs may ultimately be needed for risk thresholds to define where CVD risk starts, but more race-specific data are needed to define these thresholds. However, it is also clear that highly elevated Lp(a) seems to mediate risk irrespective of race, and patients who are above the 80 percentile for their race are likely at increased risk. 29 In that regard, using percentiles for risk thresholds rather than absolute values maybe a more attractive and less confusing parameter as recently suggested. 9
Limitations
Race-specific data and information on the presence or absence of CVD or diabetes mellitus was not available in these databases to tease out their role in elevated Lp(a) level cutoffs and risk thresholds. However, it is also noted that race-specific data also was not available in the EAS recommendations for which some of the comparisons are made. Data on the absence or presence of CVD were not available from the referral laboratory database, so the population reflects an all-comers population rather than population derived from the community at large. However, a prior report comparing laboratory values with those obtained from the recent National Health and Nutrition Examination survey concluded that with some caveats, the referral laboratory patient population is likely to be generally representative of the US population. 31 Apo(a) isoforms were not measured in this study; therefore, we could not analyze their relationship to Lp(a) levels. Finally, data on concomitant statin therapy was not available. We have shown recently that all currently used statins either alone or in combination with ezetimibe may raise Lp(a) levels, 32 and therefore, the true baseline values may be slightly overestimated. Nonetheless, it is also possible that the increase in Lp(a) may account for some of the residual risk in statin-treated patients and that an on-statin Lp(a) level may accurately predict risk, as shown recently. [10] [11] [12] 
